Breast Cancer Prevention Strategy to be Tested in Young Women
By Deborah Borfitz
November 17, 2026 | Researchers are leveraging involution, the natural biological clean-up and remodeling process that happens after a woman stops breastfeeding, in a quest to prevent breast cancer in young, high-risk women. While breastfeeding is “extraordinarily important” for both moms and infants, the immediate postpartum period paradoxically introduces a temporary, sharp increase in risk—most notably, for women who have BRCA1 genetic mutations, according to Christopher Maxwell, Ph.D., professor in University of British Columbia’s faculty of medicine and an investigator at BC Children's Hospital Research Institute.
Based on an analysis of health records on thousands of women in Spain and Norway, a lactation-suppressing drug known as cabergoline has been linked to a lower incidence of postpartum breast cancer. In BRCA1-mutant mouse models, a single dose completely remodeled the mammary gland, reducing leftover milk duct structures, decreasing rapid cell proliferation, and reversing local immune system exhaustion (Cancer Discovery, DOI: 10.1158/2159-8290.CD-26-0187), in a project that was led by Jesús Perez-Losada, a researcher at the Cancer Research Center, University of Salamanca.
The hypothesis here is that cabergoline should be used in high-risk women after they choose to wean “to drive a deeper winter in order to clean out the epithelium and prevent breast cancer in the postpartum period,” Maxwell says, in likening the biology of the breast to a tree across different seasons. The function of the epithelial ductal tree within the mammary gland is to transport and store milk produced by specialized sacs (alveoli). Architecturally, it resembles an inverted tree with smaller branches collecting milk and converging into larger ducts that drain out of the nipple.
The major trunk of this tree has primary, secondary, and tertiary branches that end with fruit-producing structures (terminal ductal lobular units) during lactation, he explains. “Not only does the epithelial ductal tree look like a fruit tree—it responds as a fruit tree responds.” While the woody variety gets signals from the sun and nutrients in the soil, the ductal tree receives cues from hormones.
“As the human female goes through her menstrual cycle, those hormones prepare the [mammary] gland for a pregnancy ... and if the pregnancy occurs, then another group of signals fills out the tree [gland] even more,” he continues. “Right near birth, you get a final lactogenic switch ... [that] produces milk-secreting cells, and they produce milk until the infant or the neonate is weaned.”
Weaning progresses into a succeeding winter when the leaves fall, the branches regress, and the epithelium regresses, says Maxwell, in describing the early and active phase of involution. “It is essential to prepare for a subsequent pregnancy.”
Drug Repurposing
The involution process is “somewhat the reverse of lactogenic switch,” Maxwell points out, when the mammary gland produces secretory binucleate cells as prompted by a hormone known as prolactin. Cabergoline inhibits the production of prolactin to induce involution and is therefore being used in an upcoming drug repurposing clinical trial as a potential cancer prevention strategy.
Reducing prolactin changes the environment of the mammary gland, activating the local immune population to remove binucleate epithelial cells. This has been considered a largely macrophage-dependent process, but recent research indicates that the T cell environment in the tissue is also crucial for regulating the terminal part of the epithelium (Nature, DOI: 10.1038/s41586-025-09713-5, and Nature Immunology, DOI: 10.1038/s41590-026-02579-3).
A decade ago, researchers identified the binucleate population in the mammary gland of mice, humans, and several other mammals, but the production process was unclear, he says. With a binucleation event, the separation of daughter cells from a parent cell can fail, resulting in a single, unified cell containing a double set of nuclei. Maxwell and his colleagues are interested in how mutations in BRCA1 are disrupting the standard cell division process.
The forthcoming placebo-controlled trial will enroll 55 women who are pregnant or lactating and carry the BRCA1 pathogenic variant, he reports. The cumulative lifetime risk of breast cancer among the variant carriers is up to 80% but particularly elevated in the postpartum period.
Funding for the multinational phase 2 study is coming from the Gray Foundation, with a confirmed coordinating site in Canada (Vancouver) and the England (Southampton), and a third in Spain, says Maxwell. Women in the intervention group will receive the standard dose of cabergoline, in four increments over two days, after they have independently decided to wean their infant.
Two participants will receive the oral medication for every one participant who receives the placebo, he notes. Investigators will monitor biomarkers of reduction in cancer risk in the blood and serum and leverage standard-of-care imaging, and, whenever possible, take a pre-treatment milk sample. A breast tissue sample will also be taken from the women at the time of the imaging at four to six months plus or minus two.
“We have been informed by the study in mice that the cabergoline treatment reduces the level of epithelium post-treatment,” he says, referring to lowered number of proliferative and binucleate cells in circulating blood and epithelial and fibroglandular volumes seen in images. Prolactin will also be tracked at baseline and one-week post-treatment.
Precisely the best time to apply the medication is currently unknown, and the study will hopefully shed some light, says Maxwell. “There are a lot of variables, because weaning is not an on-off process ... but we believe we’ve identified the highest risk population and weaning is the optimal time for it.”
Market Dynamics
Cabergoline is an essential, off-patent medication developed for the treatment of hyperprolactinemia, a condition where a female overproduces prolactin, and is designed to prevent its secretion, Maxwell says. The drug is used in the U.K. and in the EU to prevent lactation, in cases where mothers lose an infant in late pregnancy or early life, they have an infection (e.g., HIV) that they don’t want to transfer to the infant, or the child is unable to nurse.
The medication is inexpensive, generally well-tolerated and is approved in Canada, the EU and the U.K. to inhibit the production of milk, he adds. In the EU and U.K. only it is also approved to suppress lactation once it has been initiated, which is how cabergoline is being repurposed for potentially preventing breast cancer.
Primary breast cancer prevention in high-risk women is currently limited to surgical removal of both breasts, their fallopian tubes and ovaries, which while effective is also highly invasive. Breast cancer causes the most potential years of life lost relative to other tissue sites in younger, under-40 women, and is a serious and growing problem in western societies, says Maxwell.
According to the American Cancer Society, overall cancer incidence rates for women under age 50 are 82% higher than for men in the same age group. That is mostly attributable to breast cancer, Maxwell says, with over half of those cases estimated to occur within 5 to 10 years of pregnancy.
Prevention studies are challenging to conduct with people who are not at very high risk of having the disease based on its underlying etiology, he adds, which in this case excludes women who have never been pregnant. “We believe these binucleate alveolar cells that are milk-producing during pregnancy also occur in the [breast] tissue in non-pregnant situations, such as during the menstrual cycle, but we don’t necessarily understand it sufficiently and we don’t know if it’s prolactin-dependent.” Opportunities to prevent the disease in women who haven’t given birth may be discovered in the future.
The research team will be seeking regulatory approval of cabergoline for primary breast cancer prevention in Canada, the EU, and the U.K., says Maxwell. The plan is to have clinical studies wrapped up in three years.
In addition to the Gray Foundation, support is being provided by the Canadian Cancer Society, the Terry Fox Research Institute and Terry Fox Foundation, as well as Spain’s Ministry of Science, Innovation and Universities and its State Research Agency. None of the research would be possible without the active engagement of patients who will be providing samples in the upcoming trial, Maxwell emphasizes.


